As the UGT1A subfamily is mainly expressed in human liver, we speculate that the UGT1A1*28 and *6 polymorphisms may improve Ara-C response and OS of the AML patients through decreasing hepatic glucuronidation and increasing the systemic exposure of Ara-C. The gene discussed is UGT1A1; the disease is acute myeloid leukemia.